When performing the same analysis using the two “gold standard” drugs typically utilised in colorectal cancer treatment, namely, fluorouracil (5‐FU) and oxaliplatin, no variations in the response between MMR‐deficient and proficient CCLs were found (Figure S4). The gene discussed is MRC1; the disease is colorectal cancer.